Dihexa, Telmisartan (Candesartan, Losartan), PEPITEM, Cognitive Enhancement and the example of Pitt-Hopkins

 

A reader recently left an interesting comment on my earlier post about telmisartan. They wrote that they had been using Dihexa for a couple of months and had noticed new vocalizations and unexpected progress with toilet training in their child. They also mentioned another peptide, PEPITEM, which they had come across while reading about bone metabolism and inflammation.

This comment prompted me to look more closely at how several topics might intersect biologically: Dihexa, angiotensin receptor blockers such as telmisartan, the peptide PEPITEM, and conditions like Pitt-Hopkins syndrome.

 

What is a peptide?

Peptides are short chains of amino acids, the same building blocks that make up proteins. They act as signaling molecules in the body and regulate many biological processes. Examples of natural peptide hormones include insulin and oxytocin.

Scientists often design synthetic peptides to mimic or modify these natural signals. Some peptides have become successful medicines. A well-known example is semaglutide, used to treat diabetes and obesity.

In recent years peptides have become very popular in longevity and biohacking circles. This is partly because modern biology has discovered many new peptide signaling systems. These regulate metabolism, immune responses, tissue repair, and brain plasticity.

Another reason is that peptide manufacturing has become much cheaper. Automated peptide synthesis now allows laboratories to produce peptides easily. As a result, some research peptides are now sold online.

Many of these compounds are marketed as “research chemicals”. Examples often discussed online include BPC-157 and Dihexa. These compounds originated in laboratory research.

However, most of them have not gone through proper human clinical trials. Their long-term safety and effectiveness are therefore unknown.

Social media and podcasts have amplified interest in these substances. This has created a large grey market for experimental peptide therapies.

Scientists remain cautious because peptides can have strong biological effects. Problems can include uncertain purity, incorrect dosing, and lack of safety data.

Despite these concerns, peptides remain an important area of medical research. Many future medicines are likely to be peptide-based.

The reason is simple, biology uses peptides as a major language of cellular communication. They control processes ranging from metabolism to immune function and brain signaling.

This is why peptides sometimes appear in discussions of neurological conditions.

Many pathways involved in brain development and synaptic plasticity are regulated by peptide signals.

  

Dihexa and the angiotensin system

Dihexa was originally developed from angiotensin IV, a fragment of angiotensin II that belongs to the renin–angiotensin system. While this system is best known for regulating blood pressure, it also has important roles in the brain.

In the 1990s researchers noticed that angiotensin IV could improve learning and memory in animal experiments. This led scientists to design molecules that could mimic these effects but cross the blood–brain barrier and remain stable in the body. One of these molecules was Dihexa.

Interestingly, Dihexa does not appear to work primarily through classical angiotensin receptors. Instead it activates the HGF/MET pathway, which regulates neuronal growth, dendritic branching and synapse formation. In laboratory experiments Dihexa has shown very strong synaptogenic effects, meaning it can promote the formation of new synaptic connections between neurons.

This is why it sometimes appears in discussions of cognitive enhancement or experimental neurological treatments. However, it is important to stress that Dihexa has never undergone proper human clinical trials, so its safety profile and long-term effects remain unknown. It is somewhat surprising that it is sold online as a “supplement” or research compound, since it is really a laboratory-designed molecule rather than a traditional dietary supplement.

 

BDNF and synaptic plasticity

Some autism clinicians have experimented with approaches intended to increase brain levels of BDNF (brain-derived neurotrophic factor), a key regulator of synaptic plasticity and neuronal survival.

BDNF promotes dendritic growth, synapse formation and learning-related plasticity. In many ways it is one of the brain’s central “growth signals”. Dihexa became famous in neuroscience circles partly because some laboratory studies suggested it could stimulate synapse formation even more strongly than BDNF, although those findings were mainly from cell culture experiments.

The two pathways are different but converge on similar intracellular signaling networks that regulate synaptic growth.

Interestingly, one of the most reliable ways to increase BDNF is not a drug at all but physical exercise. Exercise stimulates BDNF production in the hippocampus through a combination of increased neuronal activity, metabolic signaling and muscle-derived molecules such as irisin. High-impact activity may also stimulate endocrine signals from bone, including osteocalcin, which can influence brain function.

 

Angiotensin receptor blockers and the brain

The drugs discussed in some of my previous articles—telmisartan, candesartan and losartan—belong to the class of angiotensin receptor blockers (ARBs). They block the AT1 receptor, which is activated by angiotensin II.

Although these drugs are prescribed for hypertension, the brain has its own local renin–angiotensin system. In the central nervous system angiotensin signaling influences neuroinflammation, oxidative stress, cerebral blood flow and neuronal excitability.

Blocking the AT1 receptor tends to reduce inflammatory signaling and shift the balance toward protective pathways.

Telmisartan is particularly interesting because it also activates the nuclear receptor PPAR-gamma, which influences mitochondrial function, metabolic signaling and inflammation in neurons.

Candesartan is often considered one of the more brain-penetrant ARBs and has shown neuroprotective effects in some experimental models.

Losartan has attracted attention because it can reduce excessive TGF-beta signaling, a pathway involved in inflammation and tissue remodeling.

Telmisartan might theoretically be more relevant in autism where metabolic stress and inflammation dominate (because of PPAR-γ activation). Losartan might be more relevant where excessive tissue-remodeling or TGF-β signaling plays a role. In the brain, tissue remodeling involves:

• synapse formation and elimination
• growth of dendrites and axons
• restructuring of the extracellular matrix around neurons
• activation of glial cells

Losartan is used to treat Marfan syndrome. Marfan syndrome is a systemic connective-tissue disorder that affects many parts of the body, particularly the heart.

Some studies have reported altered TGF-β signaling in certain forms of autism, suggesting that immune and tissue-remodeling pathways may contribute to aspects of neurodevelopment in at least some individuals. Losartan could theoretically influence these biological processes.

These mechanisms do not directly overlap with Dihexa’s synapse-forming activity, but they may influence the overall biological environment in the brain by reducing inflammatory and metabolic stress.

 

The peptide PEPITEM

The reader also mentioned PEPITEM, short for “PEPtide Inhibitor of Trans-Endothelial Migration”.

PEPITEM regulates the movement of immune cells across blood vessel walls. In simple terms, it helps control whether inflammatory immune cells leave the bloodstream and enter tissues.

This pathway has been studied mainly in inflammatory diseases. By limiting immune-cell migration, the PEPITEM pathway can reduce tissue inflammation.

Interestingly, the same pathway also influences bone metabolism because immune signaling strongly affects osteoclast activity and bone resorption.

 

Why bone biology keeps appearing

One surprising theme linking these topics is the intersection between inflammation, bone metabolism and the renin–angiotensin system.

Angiotensin II can stimulate osteoclast activity and promote bone resorption. Blocking the AT1 receptor with ARBs may therefore modestly reduce inflammatory bone loss. Some observational studies have suggested that ARB use may be associated with slightly higher bone density or lower fracture risk.

Given how closely immune signaling and bone metabolism interact, it is not surprising that peptides affecting immune-cell trafficking, like PEPITEM, also influence bone remodeling pathways.

 

Pitt-Hopkins syndrome as an example

Pitt-Hopkins syndrome is caused by mutations in the transcription factor TCF4. This gene regulates many downstream processes involved in neuronal development, synaptic maturation and network formation.

In experimental models of Pitt-Hopkins and related neurodevelopmental disorders, researchers often observe abnormalities in synaptic development and neuronal connectivity.

Because of this, some therapeutic ideas have focused on pathways that influence synaptic plasticity, neuronal growth or inflammatory signaling.

The HGF/MET pathway activated by Dihexa is one such pathway. The MET gene has also been linked to autism genetics in several studies, and reduced MET signaling has been associated with altered cortical connectivity.

This does not mean that Dihexa is a treatment for Pitt-Hopkins syndrome or autism, but it is certainly plausible.

We saw in previous posts that autism can be broadly divided in hypo/hyper (too little/much) active pro-growth signaling pathways. Pitt Hopkins would be in the hypo category, so increasing activity should be beneficial.

The unknown issue with Dihexa is that it has not be tested thoroughly in humans, so long term use might not be wise, particularly in older people.

The totally safe way to increase pro-growth signaling is via daily aerobic exercise, which comes up again in the next post, which looks at translating recent Alzheimer's research to autism. 

 

A broader pattern

What the reader’s comment illustrates is something that appears frequently in biomedical research, apparently unrelated compounds often converge on a small number of biological control systems.

In this case we see several different layers of regulation:

– the renin–angiotensin system influencing inflammation and metabolic signaling
– growth factor pathways such as HGF/MET and BDNF regulating synapse formation
– immune trafficking pathways such as PEPITEM controlling inflammatory cell migration
– transcriptional regulators such as TCF4 governing neuronal development

Each operates at a different level, but they all ultimately influence how neurons grow, connect and function.

This does not mean that compounds like Dihexa or peptides such as PEPITEM will become treatments for neurological conditions. Most remain at a very early stage of research.

But it does highlight how discoveries in cardiovascular biology, immunology, bone metabolism and neuroscience increasingly intersect.

 

Conclusion

Dihexa and telmisartan start from the same hormonal system but act very differently:

• Dihexa directly stimulates synapse formation through growth-factor signaling.
• Telmisartan reduces inflammation and metabolic stress that may impair neuronal function.

The overlap lies mainly in their potential downstream effects on neuronal plasticity, not in their primary mechanism of action.

In the case of Pitt Hopkins syndrome both might be potentially beneficial, although through very different mechanisms, but no clinical evidence exists.

Dihexa acts by activating the HGF/MET pathway, which promotes synapse formation, dendritic growth and neuronal plasticity. Since Pitt-Hopkins syndrome involves impaired neuronal network development caused by mutations in the TCF4 transcription factor, pathways that enhance synaptic growth should attract scientific interest.

Telmisartan works in a different way. By blocking the AT1 receptor of the renin–angiotensin system it reduces inflammatory signaling and oxidative stress, and it also activates the nuclear receptor PPAR-γ, which influences mitochondrial metabolism and cellular stress responses. These effects could potentially improve the cellular environment in which neurons function.

In simple terms, Dihexa attempts to directly stimulate synapse formation, whereas telmisartan may reduce biological stresses that interfere with normal neuronal signaling.

Both approaches therefore touch on biological processes that are relevant to brain development and plasticity.

Dihexa is used by some autism clinicians in the US.

 

Up to 40% of children in the “failed” phase 3 bumetanide trial were actually responders, according to AI reanalysis of the data – Treating autism in the real world

 

In some parts of the world even the words “treating autism” can still get you into trouble and some people have to go to quite extreme lengths to get their child’s developmental trajectory back on track.

I did note that in the US big changes have been made to their Interagency Autism Coordinating Committee (IACC) that coordinates all efforts within the Department of Health and Human Services (HHS) concerning autism. Now it includes some readers of this blog. Will this make a difference?

https://iacc.hhs.gov/ 

 

Over in France, the Bumetanide researchers Ben-Ari, Lemonnier and pals published their AI driven reanalysis of the “failed” phase 3 autism trial. They found that using AI they could actually predict who did actually respond; and many did. Nonetheless this large trial of all-jumbled-together kids with an autism diagnosis showed that overall bumetanide was no better than a placebo. Sounds strange to you? This is a common theme in autism trials because they do not narrow down a specific type of autism that they are trying to treat.

Over where I am, I keep getting positive reports of success. Some people are lucky and find that much of what works for my son works for theirs. There is a lot in this blog about other types of autism.

Why autism remains untreatable?

Autism is not simple to treat. Autism has no biological definition and measurement scales are all likely not fit for purpose. What would treatment success even mean?

From the perspective of severe autism with apparent ID (the old “Classic autism”) the biggest issues are to do with the slow rate of acquiring new skills. There are very well established tools to measure the skillset of such kids, such as  ABLLS (Assessment of Basic Language and Learning Skills). There are also non-verbal IQ tests. 

For young kids with classic autism you want them to add these basic skills ASAP, so that they can move on with their lives. In our case Bumetanide was the key to unlock new skill addition.

This is not what the phase 3 bumetanide trial was trying to measure.

Indeed one of the recurring comments from parents and teachers is the child has become more “present.” How do you quantify something like that?

For most children with autism in 2026, they do not have a problem with skill acquisition, they are a bit quirky, nervous, resistant to change, stim a bit, do not make friends. It is a very different condition. These issues are very real and genuinely concern some parents, but they are very different problems.

The modern cookie-cutter, protocol-driven, approach does work for most of medicine. But it will never work on an ill-defined category like autism. It actually becomes ridiculous when you look at all the varied types of autism. Even people with cerebral palsy or Down syndrome can be given an “autism” diagnosis on top, but they are completely different biological conditions.

Where to from here?

What does Ben-Ari do now?

Start again with another phase 3 trial? Paid for by who?  Will Servier come back and fund the second attempt?

In the meantime the clock keeps ticking.

I read Ben-Ari’s initial study and made my n=1 trial in 2012. My trial met its primary endpoint (Peter satisfied) and therapy started.

Academic performance went from complete basket-case to passing his high school public IGCSE exams a decade later.

Now it is 2026 and therapy still continues. No side effects,  heart ultrasound (echocardiogram) all normal.

Crazy world.

40% “disabled” at Stanford

I was surprised to read that almost 40% of undergraduates at Stanford University are claiming disability, to get extra time in exams. It does tell you a lot about the current generation of 20 year olds.

I would give them an E on their final diploma (I passed but needed Extra time). It is perfectly reasonable for a small number of clever students to need extra time, they might have a physical disability with their hands, be deaf, or blind, or dyslexic. It is perfectly reasonable to give some people extra time, but 40%?

It really is not fair on the remaining 60%. Maybe just give everyone an extra hour, those that finish early just leave early. They could get E on their results, for “I work fast and finish Early - hire me!"

What is annoying is the trivialization of the word disability.

40% of Stanford undergrads receive disability accommodations—but it’s become a college-wide phenomenon as Gen Z try to succeed in the current climate

So many people claim a disability like autism that theme parks in the US and Europe have had to roll back their privileged access schemes.

When I visited Charlotte International airport a while back and had to stand in a very long line for the passport control, I was amazed to see a never-ending procession of people appearing in wheelchairs to skip the queue. I have never seen this in Europe, but I suppose it will eventually come.

 

Back to those 40% in the Bumetanide trial.

New Analysis of the Bumetanide Phase 3 Trials: Were Responders Hidden in a “Failed” Study?

Approximately one-quarter to one-third of participants fit validated clinical profiles in which bumetanide showed statistically significant benefit on SRS-2, despite the overall trial being negative. The abstract itself says up to 40%.

Treating autism with Bumetanide: Identification of responders using Q-Finder machine learning algorithm

Bumetanide, a specific NKCC1 co-transporter inhibitor, restores deficient GABAergic inhibition implicated in various brain disorders, including Autism Spectrum Disorders (ASD). In keeping with this mechanism, nine successful phase 2 clinical trials, conducted by seven independent teams using an identical protocol, have shown significant improvements in ASD symptoms among individuals treated with Bumetanide. Despite these promising results, two large phase 3 clinical trials (over 400 children recruited in approximately 50 centers and covering age groups 2–6 and 7–17 years) failed with no significant difference between patients treated by placebo or Bumetanide. This failure may stem from the substantial heterogeneity of ASD symptom profiles across the study population, potentially diluting the overall observed treatment effect. To address this, we reanalyzed the phase 3 data using Q-Finder, a supervised machine learning algorithm, aiming to identify subgroups of patients who responded to the treatment. This analysis was based on clinical parameters collected at the baseline of trial and used the same standard endpoints and success criteria defined in the original phase 3 protocol. It enabled the identification of responder subgroups showing a statistically significant difference between placebo and Bumetanide treatment arms. We report detailed descriptions and statistical evaluations of these subgroups. The discovered responder subgroups, representing up to 40% of participants, were cross validated between the two study populations. These findings suggest that meaningful treatment responses can be uncovered within negative phase 3 trials, highlighting the limitations of a one-size-fits-all approach for heterogeneous conditions such as ASD. Machine learning appears to be a promising tool to support this precision medicine strategy.

The 2026 reanalysis published in Translational Psychiatry revisited the large Phase 3 bumetanide trials that previously failed to meet their primary endpoint.

The original Phase 3 trials included more than 400 children (ages 2–17) and found no significant overall difference between bumetanide and placebo on the primary outcome measure (CARS2).

This new study asked a different question:

Instead of “Did bumetanide work for everyone?”, could it have worked for specific subgroups that were diluted in the overall average?

To explore this, the authors used a supervised machine-learning algorithm (Q-Finder) to identify baseline clinical profiles associated with treatment response.

What They Found

The original overall result remains negative

Across the entire population:

• No significant benefit on the primary endpoint (CARS2).
• No meaningful average effect.

So the trial still officially failed.

Subgroups showing benefit were identified

When the data were stratified by symptom profiles at baseline, several subgroups showed:

• Statistically significant improvement on the SRS-2 (Social Responsiveness Scale)
• Treatment effects of roughly 12–17 points in validated groups
• Coverage of about 25–36% of participants in the largest responder profiles

Importantly, these findings were cross-validated between the younger and older trial cohorts.

A Consistent Feature of Responders

Across validated subgroups, one feature repeatedly appeared:

Mildly abnormal “adaptation to environmental changes” on CARS2

This domain reflects:

• Difficulty with transitions
• Rigidity around routines
• Stress with change

Responders were typically:

• Clearly autistic (often moderate–severe social symptoms)
• With repetitive behaviours
• But not globally or profoundly impaired across all domains

Interestingly, IQ did not emerge as a defining predictor of response.

Primary Endpoint vs Secondary Endpoint

A key nuance:

• No validated responder subgroups were found using the primary endpoint (CARS2).
• Validated subgroups were found using the secondary endpoint (SRS-2).

From a regulatory standpoint, this matters: trials are judged on their primary endpoint.

From a scientific standpoint, it suggests:

SRS-2 may have been more sensitive to the type of change bumetanide produces.

What This Means

This reanalysis does not prove bumetanide works broadly in autism.

It does suggest:

• Autism is highly heterogeneous.
• A one-size-fits-all trial design may dilute effects.
• A biologically or symptom-stratified approach may be necessary.
• Around one-quarter to one-third of participants may represent a responder subtype.

However, these findings are post hoc and exploratory.

To confirm them, a new trial would need to:

• Prospectively enroll only the identified responder phenotype.
• Use appropriate primary endpoints.
• Replicate the treatment effect.

Why This Matters for Autism Research

The study reflects a broader shift toward precision medicine:

• Rather than asking “Does this drug work for autism?”
• The better question may be:

“Which subtype of autism does it work for?”

Machine learning may help identify these subgroups, but prospective validation is essential.

The original Phase 3 trial remains negative at the population level.

This reanalysis suggests that meaningful responses may have been present in specific clinical subgroups — particularly children with:

• Mild adaptation abnormalities
• Repetitive behaviours
• Significant social impairment

Whether this represents a reproducible biological subtype remains to be tested in future trials.

Conclusion

In Rett syndrome a very expensive new drug called Trofinitide was approved, even though reports suggest it is only really effective in about 20% of these girls. I was really surprised.  It costs $300,000 to $900,00 a year depending on the girl’s weight.

It looks very odd that the large bumetanide failed, even though 25-40% were actually responders. By the way, my son’s bumetanide therapy has cost about $80 a year, for the last 13 years.

It does not fill you with great confidence.

I recently saw an article saying that “paracetamol/ acetaminophen does not, after all, increase the incidence of autism.” Well theoretically it should be harmful, by depleting glutathione, which is why it should be taken with NAC. We also know that NAC taken during pregnancy can significantly reduce the risk of miscarriage and this has been studied in a clinical trial.

N-acetyl cysteine for treatment of recurrent unexplained pregnancy loss

A controlled clinical trial studied N-acetylcysteine (NAC) in 168 pregnant women with a history of recurrent unexplained miscarriage. Women received either folic acid alone or folic acid plus NAC at 600 mg per day. In the NAC group, 52% of pregnancies continued beyond 20 weeks, compared with 27% in the control group. The take-home baby rate was 47% in the NAC group, compared with 21% in the control group. This represents more than a doubling of the live birth rate. NAC works by restoring glutathione, the cell’s main antioxidant, protecting placental and fetal tissue from oxidative stress. Oxidative stress is known to impair placental function and contribute to pregnancy loss. NAC was well tolerated, with no significant safety concerns reported. These results suggest that correcting oxidative stress can directly improve pregnancy outcomes in a defined high-risk group. This study illustrates how targeting a specific biological mechanism can dramatically change developmental outcomes.

If a professionally-managed autism trial cannot detect the 25-40% who responded to some extent, do you believe a study that effectively says nobody gets autism from pre-natal acetaminophen. Not even 1%? All you likely need to do is pair it with NAC to make the risk 0%.

For decades doctors refused to believe regressive autism existed. Once people started videoing their toddlers, it became impossible to doubt that some actually had developed speech and then lost it. Parents were not imagining it. It was just an inconvenient truth, and still is.

A maximalist intervention strategy – Alibek’s treatment for regressive autism driven by reactivation of a latent viral infection

Minimalist vs maximalist, the choice is yours

In my last post I introduced the concept of nudge treatments for autism at one extreme, to the sledgehammer at the other.

Today we are looking at the number of treatments used at once. It goes from cautious/minimalist to maximalist.

Dr Ken Alibek is known for his earlier role in the former Soviet biological weapons programme before later working in biodefence and virology in the United States. In recent years, he has proposed that a subset of regressive autism may be driven by latent viral infection and antibody-dependent enhancement (ADE), leading to chronic neuroinflammation.

It is relevant to mention that Dr Alibek has a daughter with autism. That personal connection clearly shapes his interest in identifying a biological mechanism and targeted therapy for a very specific autism. There is nothing unusual about this — many researchers are motivated by personal experience — but it helps explain why his model focuses on a specific immune-mediated, regressive subtype rather than autism as a whole.

His ideas have attracted interest within biomedical autism circles, particularly among parents of children with sudden regression. In mainstream academic medicine, however, the theory remains unproven and largely speculative pending stronger clinical evidence.

Dr Alibek’s approach is not simple polytherapy, but a high-intensity, multi-layer protocol that simultaneously targets viral reactivation, immune activation, inflammation, and gut dysbiosis.

It is a maximalist intervention strategy.

It is very different to Peter’s, step-by-step, personalized polytherapy approach, which looks very cautious when you compare them.

 

The ADE autism hypothesis

Dr Alibek proposes that a subset of regressive autism is driven by latent viral infection in the brain. The viruses implicated are mainly herpesviruses such as HHV-6, CMV, HSV, rubella, or varicella.

These infections occur early in life (in utero or infancy) and persist in a dormant state.
The child produces antibodies, but they are non-neutralising — meaning they bind the virus without fully blocking it.

Later, an immune trigger such as fever or infection reactivates the latent virus. Instead of protecting the child, the existing antibodies facilitate viral entry into immune cells via Fc receptors — the antibody-dependent enhancement (ADE) pathway.

This leads to amplified viral activity inside immune cells.

·        Microglia in the brain become activated.

·        Cytokines and inflammatory mediators are released.

·        Synaptic function is disrupted.

The result is abrupt developmental regression — often described by parents as a sudden “cliff.”

The model attempts to explain regression after fever, immune-triggered worsening, and chronic neuroinflammation seen in some autism studies. It applies specifically to a regressive, immune-sensitive subtype — not to all autism.

 

Appraisal

The model is biologically plausible and internally coherent.
However, ADE has not been demonstrated in herpesviruses in this context, and controlled clinical evidence is lacking.

Clinical improvement on his multi-drug protocol does not by itself validate the ADE mechanism.

For antibody-dependent enhancement (ADE) to occur, three things must be present:

·        The virus must be actively replicating and producing viral particles.

·        Antibodies must bind to those viral particles without fully neutralising them.

·        The antibody–virus complex must then enter immune cells via Fc receptors.

 

In other words, ADE requires active virus in circulation.

A virus that is truly dormant (latent) inside cells cannot trigger ADE, because there are no viral particles available for antibodies to bind.

This has an important implication for treatment.

If the therapy works only while antivirals are being taken, then it is acting as long-term viral suppression — similar to how recurrent herpes infections are managed.

However, if a single 30-day course produces lasting improvement, then something more than simple viral suppression must have occurred. That would suggest either a change in immune regulation or a different underlying mechanism altogether.

 

Lab features that would fit the ADE / viral reactivation subtype

Evidence of herpesvirus reactivation

More meaningful than just high IgG:

• Positive viral PCR (blood, saliva, CSF if done clinically)
• Detectable viral DNA load
• Rising IgG titres over time
• Positive IgM (though often absent in reactivation)
• Elevated early antigen antibodies (for EBV, for example)

 

High IgG alone is common in the general population and is not sufficient.

 

Immune Activation Profile

Markers suggesting ongoing immune stimulation:

• Elevated CD3+ T-cell counts
• Skewed CD4/CD8 ratio
• Elevated NK cell activation markers
• Elevated inflammatory cytokines (IL-6, TNF-α, IL-1β)
• Elevated CRP (even mildly)

These would support chronic immune activation.

 

Neuroinflammatory Indicators

There is no easy blood test for brain inflammation, but possible supportive markers:

• Elevated S100B
• Elevated neopterin
• Elevated CSF inflammatory markers
• Elevated serum ferritin (as inflammatory marker)

 

Mast Cell / Histamine Activation

Since the model overlaps with mast-cell activation:

• Elevated serum tryptase
• High plasma histamine
• DAO imbalance
• Clinical history of allergy, eczema, flushing

 

Clinical Phenotype

Labs alone are not enough. The clinical picture should include:

• Clear regression after fever or infection
• Worsening during immune stress
• Fluctuating course
• Temporary improvement with anti-inflammatory agents

Without this phenotype, the lab signals are less meaningful.

 

What Would NOT Be Sufficient

• High HHV-6 IgG alone
• High VZV IgG alone
• A single abnormal T-cell number
• Vague “immune imbalance”

Most adults and children are herpesvirus IgG positive.

 

What would truly support the model

The strongest evidence would be:

1.     Active viral load detected.

2.     Antiviral therapy reduces viral load.

3.     Clinical improvement correlates with viral suppression.

That would be compelling.

 

The initial Alibek therapy can include all of:

 

Antiviral Therapy

• Valacyclovir
• Ribavirin

Antibacterial / Antimicrobial

• Azithromycin
• Rifaximin 
• Artemisinin

Antifungal

• Nystatin
• Fluconazole

Anti-Inflammatory

• Ibuprofen

 

Mast Cell / Histamine Modulation

• Ketotifen
• Zyrtec (cetirizine)

Gut Support

• Sodium Butyrate
• Soluble Fiber
• Bacillus coagulans probiotic
• Digestive enzymes
• Activated charcoal

 

Neuro / Antioxidant Support

• NAC
• Omega-3 (EPA/DHA)
• Magnesium glycinate
• L-theanine
• Vitamin C
• Milk Thistle Extract

 

Methylation / Folate Support

• Folinic acid
• Methylcobalamin

General Micronutrients

• Multivitamin
• Vitamin D
• Vitamin K2

 

What is controversial?

When you look at each therapy individually, none are that controversial. All of them are on my list of possible autism therapies, that have at least some solid grounding in science.

What makes the protocol controversial is not any individual drug, but the simultaneous stacking of so many active interventions, which increases risk and makes causal interpretation extremely difficult.

Ribavirin is probably the most controversial element in that protocol.

I actually wrote about ribavirin, back in 2017, but not in relation to a virus. 

eIF4E inhibitors for Autism – Why not Ribavirin?

In 2017 I discussed ribavirin from a very different perspective. My interest was not antiviral activity, but its potential role as an inhibitor of eIF4E, a key downstream component of the mTOR pathway. Overactivity of mTOR/eIF4E signalling has been linked to synaptic protein dysregulation and excitatory/inhibitory imbalance in certain autism models. In that context, ribavirin was considered as a possible targeted modulator of translational control — a pathway-based hypothesis grounded in mouse data.

Dr Alibek’s use of ribavirin sits within a different framework. In his model, ribavirin is part of a broader antiviral strategy aimed at suppressing latent viral reactivation and reducing immune-driven neuroinflammation. The same drug is therefore being used under two very different theories: one targeting synaptic translation mechanisms, the other targeting chronic viral infection.

 

Peter’s 2017 Ribavirin Hypothesis

The reasoning was:

• mTOR overactivity is implicated in autism.
• eIF4E is a key downstream node in mTOR signalling.
• Overexpression of eIF4E causes autism-like phenotypes in mice.
• Inhibiting eIF4E corrects behaviour in animal models.
• Ribavirin inhibits eIF4E signalling.
• Therefore: ribavirin might work as a selective downstream mTOR modulator.

This was:

• Mechanistic
• Based on translational control
• Focused on E/I imbalance
• Rooted in synaptic protein synthesis

It had nothing to do with viral reactivation.

It was about translation dysregulation.

 

Alibek’s ribavirin usage

In his protocol, ribavirin appears positioned as:

• A broad-spectrum antiviral
• Part of an anti-viral / anti-infective stack
• Targeting presumed chronic viral reactivation

That is a completely different theoretical framework.

Same drug. Different logic.

 

Which Version Is More Biologically Coherent?

Peter’s 2017 argument had:

• Direct mouse model evidence
• Clear molecular target (eIF4E)
• Specific downstream mechanism
• Defined signalling pathway

Alibek’s usage is:

• Broader
• Infection-driven
• Less specific mechanistically

 

Neither hypothesis has been tested in controlled human clinical trials.

Both are biologically plausible.

Both are unproven.

Both could ultimately be partly right, completely right, or completely wrong.

 

Why Ribavirin Is Still Controversial

• Ribavirin is not a selective eIF4E inhibitor.
• It has systemic effects.
• It is not benign.
• Human autism trials do not exist.

 

Conclusion

It is not surprising that Dr Alibek’s theory has many followers. I am told that he has many happy clients.

I was struck by the number of simultaneous interventions. There are very many therapies stacked together all at once. 

Because herpes viruses establish lifelong latency (they never leave you), antivirals can only suppress active replication, not eliminate the virus. An important practical question therefore becomes: how often would such therapy need to be repeated?

If families are seeing sustained improvement, then the protocol is working for them in practice — regardless of whether the ADE explanation ultimately proves correct.

I gave up, long ago, thinking about a single standard polytherapy for autism, shifting towards a personalized polytherapy. There is so much variation among people that the more you stack interventions together it becomes inevitable that you will include one that provokes a negative reaction, or indeed no reaction. I favour the use of less interventions, just ones that are beneficial in that unique person. The only way to do that is to go step by step. You also learn from identifying which therapies provoke a negative reaction.

One blog reader in Siberia has a child with very similar therapeutic responses to my son, for example bumetanide and verapamil work very well; but there are also notable differences. For me choline was bad, but it works well in Siberia.